

Bristol Health and Wellbeing Board

Title of Paper:	Bristol Pharmaceutical Needs Assessment 2022
Author (including organisation):	Carol Slater, Head of Service Public Health, Bristol City Council
Date of Board meeting:	24 November 2022
Purpose:	Information and discussion

1. Executive Summary

Bristol City Council Health and Wellbeing Board has a statutory responsibility to assess needs for pharmaceutical services in its area every 3 years. Delegated authority for signing off this year's PNA was delegated by the Health and Wellbeing Board to the Director of Public Health at the April 2022 HWB meeting, in order to comply with mandatory timeline requirements. The Bristol 2022 pharmaceutical needs assessment (PNA) was published by 1st October 2022, as required by the national Regulations. The new PNA spans the period from 2022-2025.

2. Purpose of the Paper

To present the final 2022 Bristol Pharmaceutical Needs Assessment, which sets out the process of production, data analysis, consultation process and final outcomes.

3. Background, evidence base, and what needs to happen

The Pharmaceutical Needs Assessment (PNA) assesses how well existing services meet health needs of the people of Bristol for "necessary" pharmaceutical services. It must identify gaps and highlight priorities for future developments. It will be used by the NHS England South (South-West) team to inform decisions on future pharmaceutical commissioning intentions and when they consider applications for new or relocated premises. The NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board (BNSSG ICB), the Integrated Care System and Bristol City Council (BCC) may also use it when determining needs to commission services that might be provided by local pharmaceutical services.

A multiagency steering group was established to provide oversight of the production of the pharmaceutical needs assessment on behalf of the Health and Wellbeing Board, utilise expertise in external organisations and streamline decision making. Membership included representatives from medicines management teams in the CCG (now ICB), Healthwatch, and the local pharmacy and medical committees.

The Bristol oversight steering group considered the following matters when producing the PNA:

1. The demography of the area
2. Whether there is sufficient choice with regard to obtaining and accessing pharmaceutical services
3. The differing needs of localities in the area

4. Likely future needs.

4. Community/stakeholder engagement

The engagement process included two forms of consultation. A survey was conducted from 14 March to 17 April 2022 via the BCC website to elicit citizen's views and experience of using pharmacy services. There were 394 respondents, and their views informed the production of the draft document.

A 60 day formal public consultation was then undertaken seeking views on the draft PNA from 30 June to 29 August 2022. Consultation information was sent to local councillors and local voluntary and community organisations. Notifications were also sent to statutory stakeholders as set out in NHSE guidance and to interested parties. There were 359 responses and the PNA was amended post consultation. No PNA conclusions were changed as a result of the consultation.

5. Recommendations

The Health and Wellbeing Board are asked to note the 2022 Bristol pharmaceutical needs assessment.

6. City Benefits

A detailed data analysis by locality is included in the PNA and the distinct pattern of demography and health needs and differences between these 3 localities of Bristol are described. Relevant stakeholder groups were identified, including a range of equality groups. An Equality Impact Assessment was conducted to inform the consultation and ensure full engagement in the consultation process by the public, local organisations and professional groups (see Appendix F, PNA).

7. Financial and Legal Implications

There are no direct financial implications. In terms of legal implications, Section 128A of the National Health Service Act 2006 (NHS Act 2006) requires each Health and Wellbeing Board to assess the need for pharmaceutical services in its area and to publish a statement of its assessment. Termed a 'pharmaceutical needs assessment', the NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013, as amended (the 2013 regulations) set out the minimum information that must be contained within a pharmaceutical needs assessment and outline the process that must be followed in its development. This PNA has complied with the legal requirements.

8. Appendices

The Bristol PNA document is appended.